Benitec Biopharma Limited (NASDAQ:BNTC - Get Free Report) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $13.47 and traded as low as $11.30. Benitec Biopharma shares last traded at $11.52, with a volume of 45,701 shares trading hands.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on the company. JMP Securities reiterated a "market outperform" rating and issued a $20.00 price objective on shares of Benitec Biopharma in a research note on Thursday, May 15th. HC Wainwright reissued a "buy" rating and issued a $28.00 target price on shares of Benitec Biopharma in a report on Monday, May 19th. Finally, TD Cowen assumed coverage on Benitec Biopharma in a report on Monday, July 7th. They issued a "buy" rating on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Benitec Biopharma currently has a consensus rating of "Buy" and a consensus target price of $26.00.
Get Our Latest Report on Benitec Biopharma
Benitec Biopharma Price Performance
The stock has a fifty day moving average of $13.24 and a two-hundred day moving average of $13.02. The stock has a market cap of $309.75 million, a price-to-earnings ratio of -7.81 and a beta of 0.40. The company has a quick ratio of 14.80, a current ratio of 14.80 and a debt-to-equity ratio of 0.01.
Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12. On average, equities research analysts anticipate that Benitec Biopharma Limited will post -1.48 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Benitec Biopharma during the second quarter worth $38,000. Ameriprise Financial Inc. boosted its position in Benitec Biopharma by 138.4% during the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock worth $448,000 after purchasing an additional 20,597 shares in the last quarter. 683 Capital Management LLC purchased a new stake in Benitec Biopharma during the fourth quarter worth $452,000. Northern Trust Corp boosted its position in Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock worth $482,000 after purchasing an additional 13,425 shares in the last quarter. Finally, Informed Momentum Co LLC purchased a new stake in Benitec Biopharma during the first quarter worth $512,000. Institutional investors and hedge funds own 52.19% of the company's stock.
Benitec Biopharma Company Profile
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Read More
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access